Marken has completed its newest depot in Moscow for both clinical and commercial pharmaceutical drug storage, clinical trial services and distribution. The facility is currently available for client audits.

The facility is located in a new building and is capable of delivering services including temperature-controlled storage at all ranges from -20 and 2-8 degrees to controlled room temperature, plus liquid nitrogen storage capabilities. Dedicated space was built for drug product storage, late stage labeling, returns and destruction for rejected goods. All of the spaces and equipment are compliant with Marken’s Good Manufacturing Practice specifications.

The Moscow facility is managed by the company’s global inventory system, Solo, which offers clients real time access to live data which tracks the conditions inside the depot as well as the disposition of their materials. It also connects to Marken’s Maestro system which books and tracks all shipments into and out of the depot on a real time basis.

Wes Wheeler, Marken’s chief executive officer, said, “Russia continues to be an important global clinical trial center, with the number of Phase III clinical trials in the 3^rd quarter 2015 growing at 14% and with 203 new clinical trials approved to start in Russia in the same quarter. * With this in mind, we decided to expand our presence in this important country and build a new facility near the Sheremetyevo airport to serve our clients more efficiently.”